Use of functional imaging across clinical phases in CNS drug development

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Borsook, D ^a,b,c   Becerra, L ^a,b,c   Fava, M ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

brain; drug development; drugs; functional imaging; networks

Indexed keywords

ADALIMUMAB; ALPRAZOLAM; AMFEBUTAMONE; AMISULPRIDE; ARIPIPRAZOLE; ATOMOXETINE; AZD 6765; BOTULINUM TOXIN A; CASOPITANT; CENTRAL NERVOUS SYSTEM AGENTS; CITALOPRAM; DESIPRAMINE; DESVENLAFAXINE; DIAMORPHINE; DIAZEPAM; DULOXETINE; EMICERFONT; ESZOPICLONE; EXENDIN 4; FLUOXETINE; GLATIRAMER; GSK 598809; GUANFACINE; HALOPERIDOL; KETAMINE; LAMOTRIGINE; LEPTIN; LY 686017; NEUROKININ 1 RECEPTOR ANTAGONIST; OLANZAPINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERUCERFONT; BIOLOGICAL MARKER;

ADDICTION; ALZHEIMER DISEASE; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; BLOOD BRAIN BARRIER; BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CEREBRAL PALSY; DEPRESSION; DROWSINESS; DRUG DEVELOPMENT; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; FOOD ADDICTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GOOD CLINICAL PRACTICE; HUMAN; IRRITABLE COLON; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NEUROPATHIC PAIN; OBESITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SOCIAL PHOBIA; TREATMENT RESPONSE; VOMITING; WAKEFULNESS; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; DRUG EFFECTS; ECONOMICS; FUNCTIONAL NEUROIMAGING; METABOLISM; PROCEDURES; STANDARDS; ARTICLE; METHODOLOGY; STANDARD;

BIOLOGICAL MARKERS; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FUNCTIONAL NEUROIMAGING; HUMANS;

EID: 84880521316     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.43     Document Type: Review

References (133)

1. Drews J. Drug discovery: a historical perspective. Science 2000; 287: 1960-1964. (Pubitemid 30158662)
2. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR D) study. Psychiatr Clin North Am 2003; 26: 457-494. (Pubitemid 36583573)
3. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287: 1840-1847. (Pubitemid 34303629)
4. Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 2007; 6: 521-532. (Pubitemid 47019441)
5. Cutler R. Worldwide Clinical Trials 2011 Available from http://www.wwctrials.com.
6. Wong DF, Tauscher J, Grunder G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 2009; 34: 187-203.
7. Breivik EK, Bjornsson GA, Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clin J Pain 2000; 16: 22-28. (Pubitemid 30155392)
8. Ponce de Leon S, Lara-Munoz C, Feinstein AR, Wells CK. A comparison of three rating scales for measuring subjective phenomena in clinical research. II. Use of experimentally controlled visual stimuli. Arch Med Res 2004; 35: 157-162. (Pubitemid 38316836)
9. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003; 72: 115-127. (Pubitemid 36469860)
10. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR D) study. Psychiatr Clin North Am 2003; 26: 457-494. (Pubitemid 36583573)
11. Chen YF, Yang Y, Hung HM, Wang SJ. Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials. Contemp Clin Trials 2011; 32: 592-604.
12. Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M et al. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosomatics 2012; 81: 87-97.
13. Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry 2012; 169: 1267-1274.
14. Amin DV, Doctor RB, Girdhar AO, Shah UH. The effect of beta-adrenergic stimulation and blockade on the efflux of PGE1-like material from the isolated perfused rabbit heart. Experientia 1980; 36: 1410-1411. (Pubitemid 11185272)
15. van Wingen GA, Zylicz SA, Pieters S, Mattern C, Verkes RJ, Buitelaar JK et al. Testosterone increases amygdala reactivity in middle-aged women to a young adulthood level. Neuropsychopharmacology 2009; 34: 539-547.
16. Kraft E, Loichinger W, Diepers M, Lule D, Schwarz J, Ludolph AC et al. Levodopainduced striatal activation in Parkinson's disease: a functional MRI study. Parkinsonism Relat Disord 2009; 15: 558-563.
17. Pontari MA, Mohamed FB, Lebovitch S, Moonat S, Lebed B, Ruggieri MR et al. Central nervous system findings on functional magnetic resonance imaging in patients before and after treatment with anticholinergic medication. J Urol 2010; 183: 1899-1905.
18. Lui S, Li T, Deng W, Jiang L, Wu Q, Tang H et al. Short-term effects of antipsychotic treatment on cerebral function in drug-naive first-episode schizophrenia revealed by 'resting state' functional magnetic resonance imaging. Arch Gen Psychiatry 2010; 67: 783-792.
19. Diers M, Yilmaz P, Rance M, Thieme K, Gracely RH, Rolko C et al. Treatment-related changes in brain activation in patients with fibromyalgia syndrome. Exp Brain Res 2012; 218: 619-628.
20. Bell EC, Willson MC, Wilman AH, Dave S. Silverstone PH. Differential effects of chronic lithium and valproate on brain activation in healthy volunteers. Hum Psychopharmacol 2005; 20: 415-424. (Pubitemid 41269699)
21. Borsook D, Pendse G, Aiello-Lammens M, Glicksman M, Gostic J, Sherman S et al. CNS response to a thermal stressor in human volunteers and awake rats may predict clinical utility of analgesics. Drug Dev Res 2007; 68: 23-41. (Pubitemid 46878003)
22. Upadhyay J, Anderson J, Schwarz AJ, Coimbra A, Baumgartner R, Pendse G et al. Imaging drugs with and without clinical analgesic efficacy. Neuropsychopharmacology 2011; 36: 2659-2673.
23. Upadhyay J, Anderson J, Baumgartner R, Coimbra A, Schwarz AJ, Pendse G et al. Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine. NeuroImage 2012; 59: 3762-3773.
24. Damoiseaux JS, Rombouts SA, Barkhof F, Scheltens P, Stam CJ, Smith SM et al. Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci USA 2006; 103: 13848-13853. (Pubitemid 44413996)
25. Boveroux P, Vanhaudenhuyse A, Bruno MA, Noirhomme Q, Lauwick S, Luxen A et al. Breakdown of within-and between-network resting state functional magnetic resonance imaging connectivity during propofol-induced loss of consciousness. Anesthesiology 2010; 113: 1038-1053.
26. Tanabe J, Nyberg E, Martin LF, Martin J, Cordes D, Kronberg E et al. Nicotine effects on default mode network during resting state. Psychopharmacology (Berl) 2011; 216: 287-295.
27. Khalili-Mahani N, Zoethout RM, Beckmann CF, Baerends E, de Kam ML, Soeter RP et al. Effects of morphine and alcohol on functional brain connectivity during 'resting state': a placebo-controlled crossover study in healthy young men. Hum Brain Mapp 2012; 33: 1003-1018.
28. Newhouse PA, Potter AS, Dumas JA, Thiel CM. Functional brain imaging of nicotinic effects on higher cognitive processes. Biochem Pharmacol 2011; 82: 943-951.
29. Jenkins BG. Pharmacologic magnetic resonance imaging (phMRI): imaging drug action in the brain. Neuroimage 2012; 62: 1072-1085.
30. Detre JA, Rao H, Wang DJ, Chen YF, Wang Z. Applications of arterial spin labeled MRI in the brain. J Magn Reson Imaging 2012; 35: 1026-1037.
31. Yuksel C, McCarthy J, Shinn A, Pfaff DL, Baker JT, Heckers S et al. Gray matter volume in schizophrenia and bipolar disorder with psychotic features. Schizophr Res 2012; 138: 177-182.
32. Upadhyay J, Maleki N, Potter J, Elman I, Rudrauf D, Knudsen J et al. Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. Brain 2010; 133(Pt 7): 2098-2114.
33. Liao Y, Tang J, Ma M, Wu Z, Yang M, Wang X et al. Frontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging study. Brain 2010; 133(Pt 7): 2115-2122.
34. Harris RE, Sundgren PC, Pang Y, Hsu M, Petrou M, Kim SH et al. Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis Rheum 2008; 58: 903-907. (Pubitemid 351364893)
35. Tibbitts J, Cavagnaro JA, Haller CA, Marafino B, Andrews PA, Sullivan JT. Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals. Regul Toxicol Pharmacol 2010; 58: 243-251.
36. Dresser R. First-in-human trial participants: not a vulnerable population, but vulnerable nonetheless. J Law Med Ethics 2009 Spring; 37: 38-50.
37. Potschka H. Targeting the brain-surmounting or bypassing the blood-brain barrier. Handb Exp Pharmacol 2010; 197: 411-431.
38. Borsook D, Upadhyay J, Klimas M, Schwarz A, Coimbra A, Baumgartner R et al. Decision-making using fMRI in clinical drug development: revisiting the NK-1 receptor antagonist for pain. Drug Discov Today 2012; 17: 964-973.
39. Upadhyay J, Anderson J, Schwarz AJ, Coimbra A, Baumgartner R, Pendse G et al. Imaging drugs with and without clinical analgesic efficacy. Neuropsychopharmacology 2011; 36: 2659-2673.
40. McKie S, Richardson P, Elliott R, Vollm BA, Dolan MC, Williams SR et al. Mirtazapine antagonises the subjective, hormonal and neuronal effects of m-chlorophenylpiperazine (mCPP) infusion: a pharmacological-challenge fMRI (phMRI) study. Neuroimage 2011; 58: 497-507.
41. Gear R, Becerra L, Upadhyay J, Bishop J, Wallin D, Pendse G et al. Pain facilitation brain regions activated by nalbuphine are revealed by pharmacological FMRI. PLoS One 2013; 8: e50169.
42. Buoen C, Bjerrum OJ, Thomsen MS. How first-time-in-human studies are being performed: a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004. J Clin Pharmacol 2005; 45: 1123-1136. (Pubitemid 41361912)
43. Damoiseaux JS. Resting-state fMRI as a biomarker for Alzheimer's disease? Alzheimers Res Ther 2012; 4: 8.
44. Poston KL, Tang CC, Eckert T, Dhawan V, Frucht S, Vonsattel JP et al. Network correlates of disease severity in multiple system atrophy. Neurology 2012; 78: 1237-1244.
45. Musen G, Jacobson AM, Bolo NR, Simonson DC, Shenton ME, McCartney RL et al. Resting-state brain functional connectivity is altered in type 2 diabetes. Diabetes 2012; 61: 2375-2379.
46. Farbota KD, Bendlin BB, Alexander AL, Rowley HA, Dempsey RJ, Johnson SC. Longitudinal diffusion tensor imaging and neuropsychological correlates in traumatic brain injury patients. Front Hum Neurosci 2012; 6: 160.
47. Brier MR, Thomas JB, Snyder AZ, Benzinger TL, Zhang D, Raichle ME et al. Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. J Neurosci 2012; 32: 8890-8899.
48. Baliki MN, Petre B, Torbey S, Herrmann KM, Huang L, Schnitzer TJ et al. Corticostriatal functional connectivity predicts transition to chronic back pain. Nat Neurosci 2012; 15: 1117-1119.
49. Zhou SY, Shu C, Korth-Bradley J, Raible D, Palmisano M, Wadjula J et al. Integrated population pharmacokinetics of etanercept in healthy subjects and in patients with rheumatoid arthritis and ankylosing spondylitis. J Clin Pharmacol 2011; 51: 864-875.
50. Cutler NR, Sramek JJ. Exploratory studies: implications for drug development in Alzheimer's disease. Rev Neurol (Paris) 1998; 154(Suppl 2): S131-S136.
51. Targum SD, Pollack MH, Fava M. Redefining affective disorders: relevance for drug development. CNS Neurosci Ther 2008 Spring 14: 2-9.
52. Hubbard CS, Labus JS, Bueller J, Stains J, Suyenobu B, Dukes GE et al. Corticotropinreleasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain. J Neurosci 2011; 31: 12491-12500.
53. Jensen K, Kieser M. Blinded sample size recalculation in multicentre trials with normally distributed outcome. Biom J 2010; 52: 377-399.
54. Ridenour TA, Hall DL, Bost JE. A small sample randomized clinical trial methodology using N-of-1 designs and mixed model analysis. Am J Drug Alcohol Abuse 2009; 35: 260-266.
55. Perlstein I, Bolognese JA, Krishna R, Wagner JA. Evaluation of agile designs in first-in-human (FIH) trials-a simulation study. Aaps J 2009; 11: 653-663.
56. Nahm ML, Pieper CF, Cunningham MM. Quantifying data quality for clinical trials using electronic data capture. PLoS One 2008; 3: e3049.
57. Tedeschini E, Fava M, Papakostas GI. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach. J Clin Psychiatry 2011; 72: 98-118.
58. Adjei AA, Christian M, Ivy P. Novel designs and end points for phase II clinical trials. Clin Cancer Res 2009; 15: 1866-1872.
59. Yang Z, Zuo XN, Wang P, Li Z, LaConte SM, Bandettini PA et al. Generalized RAICAR: discover homogeneous subject (sub)groups by reproducibility of their intrinsic connectivity networks. NeuroImage 2012; 63: 403-414.
60. Leon AC. Comparative effectiveness clinical trials in psychiatry: superiority, noninferiority, and the role of active comparators. J Clin Psychiatry 2011; 72: 1344-1349.
61. Fleischhacker WW, Czobor P, Hummer M, Kemmler G, Kohnen R, Volavka J. Placebo or active control trials of antipsychotic drugs? Arch Gen Psychiatry 2003; 60: 458-464. (Pubitemid 36539054)
62. Le Henanff A, Giraudeau B, Baron G, Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. JAMA 2006; 295: 1147-1151. (Pubitemid 43352344)
63. Borsook D, Becerra L, Hargreaves R. Biomarkers for chronic pain and analgesia. Part 1: the need, reality, challenges, and solutions. Discov Med 2011; 11: 197-207.
64. Borsook D, Becerra L, Hargreaves R. Biomarkers for chronic pain and analgesia. Part 2: how, where, and what to look for using functional imaging. Discov Med 2011; 11: 209-219.
65. Founti P, Topouzis F, van Koolwijk L, Traverso CE, Pfeiffer N, Viswanathan AC. Biobanks and the importance of detailed phenotyping: a case study-the European Glaucoma Society GlaucoGENE project. Br J Ophthalmol 2009; 93: 577-581.
66. Wong DF, Grunder G, Brasic JR. Brain imaging research: does the science serve clinical practice? Int Rev Psychiatry 2007; 19: 541-558. (Pubitemid 47493740)
67. Wiedemann K. Biomarkers in development of psychotropic drugs. Dialogues Clin Neurosci 2011; 13: 225-234.
68. Hampel H, Prvulovic D, Teipel SJ, Bokde AL. Recent developments of functional magnetic resonance imaging research for drug development in Alzheimer's disease. Prog Neurobiol 2011; 95: 570-578.
69. Mattila J, Koikkalainen J, Virkki A, Simonsen A, van Gils M, Waldemar G et al. A disease state fingerprint for evaluation of Alzheimer's disease. J Alzheimer's Dis 2011; 27: 163-176.
70. Risacher SL, Shen L, West JD, Kim S, McDonald BC, Beckett LA et al. Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging 2010; 31: 1401-1418.
71. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC et al. The Alzheimer's disease neuroimaging initiative: a review of papers published since its inception. Alzheimer's Demen 2012; 8(1 Suppl): S1-68.
72. Marek K, Jennings D, Lasch S, Siderowf A, Tanner C et al. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011; 95: 629-635.
73. Johannsen P, Salmon E, Hampel H, Xu Y, Richardson S, Qvitzau S et al. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease. CNS Drugs 2006; 20: 311-325.
74. Dolgin E. Fluctuating baseline pain implicated in failure of clinical trials. Nat Med 2010; 16: 1053.
75. Kemp AS, Grossberg GT, Romano SJ, Arnold DL, Ryan JM, Bullock R et al. Trial designs likely to meet valid long-term Alzheimer's disease progression effects: learning from the past, preparing for the future. Int J Alzheimers Dis 2009; 2009: 949271.
76. Geisser ME, Clauw DJ, Strand V, Gendreau RM, Palmer R, Williams DA. Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran. Pain 2010; 149: 373-378.
77. Oeltjenbruns J, Schafer M. [Clinical significance of the placebo effect]. Anaesthesist 2008; 57: 447-463.
78. Pollo A, Benedetti F. The placebo response: neurobiological and clinical issues of neurological relevance. Prog Brain Res 2009; 175: 283-294.
79. Benedetti F, Carlino E, Pollo A. How placebos change the patient's brain. Neuropsychopharmacology 2011; 36: 339-354.
80. Dworkin RH, Katz J, Gitlin MJ. Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain. Neurology 2005; 65(12 Suppl 4): S7-S19.
81. Cutler NR, Sramek JJ, Murphy MF, Riordan H, Biek P, Carta A. Critical Pathways to Success in CNS Drug Development 1 edn 2010.
82. Kemp AS, Schooler NR, Kalali AH, Alphs L, Anand R, Awad G et al. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull 2010; 36: 504-509.
83. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009; 19: 34-40.
84. Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 2010; 71: 270-279.
85. Hughes J, Gabbay M, Funnell E, Dowrick C. Exploratory review of placebo characteristics reported in randomised placebo controlled antidepressant drug trials. Pharmacopsychiatry 2012; 45: 20-27.
86. Goodin DS, Frohman EM, Garmany GP Jr., Halper J, Likosky WH, Lublin FD et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-178. (Pubitemid 34086933)
87. Lang AE. Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med 2010; 16: 1223-1226.
88. Cummings JL. Integrating ADNI results into Alzheimer's disease drug development programs. Neurobiol Aging 2010; 31: 1481-1492.
89. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC et al. The Alzheimer's disease neuroimaging initiative: a review of papers published since its inception. Alzheimer's Dement 2012; 8(1 Suppl): S1-68.
90. O'Muircheartaigh J, Vollmar C, Barker GJ, Kumari V, Symms MR, Thompson P et al. Abnormal thalamocortical structural and functional connectivity in juvenile myoclonic epilepsy. Brain 2012; 135(Pt 12): 3635-3644.
91. Amad A, Cachia A, Gorwood P, Pins D, Delmaire C, Rolland B et al. The multimodal connectivity of the hippocampal complex in auditory and visual hallucinations. Mol Psychiatry 2013 ; PubMed PMID: 23318999, volume 24; pp 483-490.
92. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre-clinical characteristics and treatment outcomes. Cephalalgia 2004; 24: 483-490. (Pubitemid 38748030)
93. Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep 2009; 13: 301-307.
94. Kuhlmann J. Alternative strategies in drug development: clinical pharmacological aspects. Int J Clin Pharmacol Ther 1999; 37: 575-583.
95. Lonning PE. Strength and weakness of phase I to IV trials, with an emphasis on translational aspects. Breast Cancer Res 2008; 10(Suppl 4): S22.
96. Toovey S. Mefloquine neurotoxicity: a literature review. Travel Med Infect Dis 2009; 7: 2-6.
97. Nevin RL. Mefloquine prescriptions in the presence of contraindications: prevalence among US military personnel deployed to Afghanistan, 2007. Pharmacoepidemiol Drug Saf 2010; 19: 206-210.
98. Schwarz AJ, Becerra L, Upadhyay J, Anderson J, Baumgartner R, Coimbra A et al. A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes and requirements. Drug Discov Today 2011; 16: 583-593.
99. Schwarz AJ, Becerra L, Upadhyay J, Anderson J, Baumgartner R, Coimbra A et al. A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: protocol optimization and best practices. Drug Discov Today 2011; 16: 671-682.
100. Lesko LJ, Atkinson AJ Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001; 41: 347-366. (Pubitemid 32390116)
101. Lathia CD. Biomarkers and surrogate endpoints: how and when might they impact drug development? Dis Markers 2002; 18: 83-90. (Pubitemid 35191662)
102. Dimasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 2001; 69: 297-307.
103. Adams CP, Brantner VV. Spending on new drug development1. Health Econ 2010; 19: 130-141.
104. O'Dwyer L, Lamberton F, Bokde AL, Ewers M, Faluyi YO, Tanner C et al. Using support vector machines with multiple indices of diffusion for automated classification of mild cognitive impairment. PLoS One 2012; 7: e32441.
105. Haller S, Nguyen D, Rodriguez C, Emch J, Gold G, Bartsch A et al. Individual prediction of cognitive decline in mild cognitive impairment using support vector machine-based analysis of diffusion tensor imaging data. J Alzheimer's Dis, 2010; 22: 315-327.
106. Grosenick L, Klingenberg B, Katovich K, Knutson B, Taylor JE. Interpretable whole-brain prediction analysis with GraphNet. NeuroImage 2013; 72: 304-321.
107. Douaud G, Menke RA, Gass A, Monsch AU, Rao A, Whitcher B et al. Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease. J Neurosci 2013; 33: 2147-2155.
108. Seminowicz DA, Wideman TH, Naso L, Hatami-Khoroushahi Z, Fallatah S, Ware MA et al. Effective treatment of chronic low back pain in humans reverses abnormal brain anatomy and function. J Neurosci 2011; 31: 7540-7550.
109. Metz AE, Yau HJ, Centeno MV, Apkarian AV, Martina M. Morphological and functional reorganization of rat medial prefrontal cortex in neuropathic pain. Proc Natl Acad Sci USA 2009; 106: 2423-2428.
110. Radley JJ, Sisti HM, Hao J, Rocher AB, McCall T, Hof PR et al. Chronic behavioral stress induces apical dendritic reorganization in pyramidal neurons of the medial prefrontal cortex. Neuroscience 2004; 125: 1-6. (Pubitemid 38402153)
111. Robinson TE, Kolb B. Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology 2004; 47(Suppl 1): 33-46. (Pubitemid 39298251)
112. Oliveira JF, Dias NS, Correia M, Gama-Pereira F, Sardinha VM, Lima A et al. Chronic stress disrupts neural coherence between cortico-limbic structures. Front Neural Circuits 2013; 7: 10.
113. Schwarz AJ, Becerra L, Upadhyay J, Anderson J, Baumgartner R, Coimbra A et al. A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes and requirements. Drug Discov Today 2011; 16: 583-593.
114. Schwarz AJ, Becerra L, Upadhyay J, Anderson J, Baumgartner R, Coimbra A et al. A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: protocol optimization and best practices. Drug Discov Today 2011; 16: 671-682.
115. Borsook D. Neurological diseases and pain. Brain 2012; 135(Pt 2): 320-344.
116. Gountouna VE, Job DE, McIntosh AM, Moorhead TW, Lymer GK, Whalley HC et al. Functional Magnetic Resonance Imaging (fMRI) reproducibility and variance components across visits and scanning sites with a finger tapping task. NeuroImage 2010; 49: 552-560.
117. Zou KH, Greve DN, Wang M, Pieper SD, Warfield SK, White NS et al. Reproducibility of functional MR imaging: preliminary results of prospective multi-institutional study performed by Biomedical Informatics Research Network. Radiology 2005; 237: 781-789. (Pubitemid 41636363)
118. Loubinoux I, Carel C, Alary F, Boulanouar K, Viallard G, Manelfe C et al. Within-session and between-session reproducibility of cerebral sensorimotor activation: a test-retest effect evidenced with functional magnetic resonance imaging. J Cerebral Blood Flow Metab 2001; 21: 592-607. (Pubitemid 32422880)
119. Thirion B, Pinel P, Meriaux S, Roche A, Dehaene S, Poline JB. Analysis of a large fMRI cohort: Statistical and methodological issues for group analyses. NeuroImage 2007; 35: 105-120.
120. Thirion B, Pinel P, Tucholka A, Roche A, Ciuciu P, Mangin JF et al. Structural analysis of fMRI data revisited: improving the sensitivity and reliability of fMRI group studies. IEEE Trans Med Imaging 2007; 26: 1256-1269. (Pubitemid 47383446)
121. Olman CA, Yacoub E. High-field FMRI for human applications: an overview of spatial resolution and signal specificity. Open Neuroimaging J 2011; 5: 74-89.
122. Chen W, Ugurbil K. High spatial resolution functional magnetic resonance imaging at very-high-magnetic field. Top Magn Resonan Imaging 1999; 10: 63-78. (Pubitemid 29288714)
123. Yacoub E, Harel N, Ugurbil K. High-field fMRI unveils orientation columns in humans. Proc Natl Acad Sci USA 2008; 105: 10607-10612.
124. Doyle OM, De Simoni S, Schwarz AJ, Brittain C, O'Daly OG, Williams SC et al. Quantifying the attenuation of the ketamine phMRI response in humans: a validation using antipsychotic and glutamatergic agents. J Pharmacol Exper Ther 2013; 345: 151-160.
125. De Simoni S, Schwarz AJ, O'Daly OG, Marquand AF, Brittain C, Gonzales C et al. Testretest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers. NeuroImage 2013; 64: 75-90.
126. Borsook D, Upadhyay J, Klimas M, Schwarz AJ, Coimbra A, Baumgartner R et al. Decision-making using fMRI in clinical drug development: revisiting NK-1 receptor antagonists for pain. Drug Discov Today 2012; 17: 964-973.
127. van Riemsdijk MM, Sturkenboom MC, Pepplinkhuizen L, Stricker BH. Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide casecontrol study in the Netherlands. J Clin Psychiatry 2005; 66: 199-204. (Pubitemid 40314326)
128. Toovey S. Mefloquine neurotoxicity: a literature review. Travel Med Infect Dis 2009; 7: 2-6.
129. Murphy SE, Mackay CE. Using MRI to measure drug action: caveats and new directions. J Psychopharmacol 2011; 25: 1168-1174.
130. Becerra L, Schwartzman RJ, Kiefer RT, Rohr P, Moulton EA, Wallin D et al. CNS measures of pain responses pre-and post-anesthetic ketamine in a patient with complex regional pain syndrome. Pain Med 2009 PubMed PMID: 19254342. Epub 2009/03/04. Eng.
131. Brooks DJ, Pavese N. Imaging biomarkers in Parkinson's disease. Prog Neurobiol 2011; 95: 614-628.
132. Sperling R. Potential of functional MRI as a biomarker in early Alzheimer's disease. Neurobiol Aging 2011; 32(Suppl 1): S37-S43.
133. Zeng LL, Shen H, Liu L, Wang L, Li B, Fang P et al. Identifying major depression using whole-brain functional connectivity: a multivariate pattern analysis. Brain 2012; 135(Pt 5): 1498-1507.